caffeine + flurbiprofen + omeprazole + midazolam

This drug combination is a cytochrome P450 (CYP) probe cocktail consisting of caffeine, flurbiprofen, omeprazole, and midazolam. It is designed to simultaneously evaluate the enzymatic activity of multiple CYP isoforms: caffeine serves as a probe for CYP1A2, flurbiprofen for CYP2C9, omeprazole for CYP2C19, and midazolam for CYP3A4. In clinical pharmacology research, such as the studies led by Min Kyu Park, this cocktail is used to phenotypically assess baseline metabolic activity and quantify the inductive or inhibitory effects of other substances, such as dexamethasone, on these specific metabolic pathways. By measuring the plasma concentrations or metabolite ratios of these probe drugs, researchers can determine the metabolic status of individuals and evaluate potential drug-drug interactions.

Other names

CYP probe cocktailCYP cocktailCYP probe cocktail-Min Kyu Park